Reuters logo
Achillion hepatitis C drug shows promise in early trial
September 27, 2012 / 12:40 PM / 5 years ago

Achillion hepatitis C drug shows promise in early trial

(Reuters) - Achillion Pharmaceuticals Inc said an early-stage trial of its experimental hepatitis C treatment showed that a single dose of the drug significantly reduced the severity of the infection.

The early-stage trial tested the drug in doses ranging from 25 mg to 1,000 mg in patients with genotype 1a. The drug, called ACH-3102, was well tolerated at all doses in which it was tested.

Based on the trial data, Achillion initiated a pilot mid-stage trial evaluating the drug in combination with ribavirin - a standard-of-care - for the treatment of chronic hepatitis C patients with genotype 1b.

The company has three more hepatitis C drugs in its pipeline.

Achillion shares closed at $9.49 on Wednesday on the Nasdaq.

Reporting by Esha Dey in Bangalore; Editing by Roshni Menon

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below